Nonsurgical interventions for peyronie disease: 2011 update

Journal of Andrology

Volumn 33, Issue 1, 2012, Pages 3-14

  Schaeffer, Anthony J ^a   Burnett, Arthur L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Medical treatment; Penile induration; Penis

Indexed keywords

4 AMINOBENZOIC ACID; ALPHA TOCOPHEROL; COLCHICINE; COLLAGEN; COLLAGENASE; CYTOKINE; DEXAMETHASONE; FIBRIN; ICOSANOID; LEVACECARNINE; MAGNESIUM SULFATE; NICARDIPINE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROPIONYL CARNITINE; TAMOXIFEN; TRIFLUOPERAZINE; UBIDECARENONE; UNCLASSIFIED DRUG; VERAPAMIL;

ANGINA PECTORIS; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DYSPEPSIA; ERECTILE DYSFUNCTION; EXTRACORPOREAL LITHOTRIPSY; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; IONTOPHORESIS; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PAINFUL ERECTION; PATHOPHYSIOLOGY; PENILE FIBROSIS; PEYRONIE DISEASE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCAR; SEIZURE; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; TRACTION THERAPY; TUNICA ALBUGINEA; VOMITING; WOUND HEALING;

HUMANS; MALE; PENILE INDURATION;

EID: 84856970775     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.110.010561     Document Type: Review

References (74)

1. Abdel-Salam Y, Budair Z, Renner C, Frede T, Rassweiler J, El-Annany F, El-Magraby H, El-Akkad M. Treatment of Peyronie disease by extracorporeal shockwave therapy: evaluation of our preliminary results. J Endourol. 1999;13:549-552.
2. Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie disease. Int J Impot Res. 1999;11:207-212.
3. Appenzeller S, Hazel E. Pentoxifylline for the treatment of anterior uveitis in Behcet's disease: possible alternative for TNF blockers. Rheumatol Int. 2009 [Epub ahead of print]. DOI: 10.1007/500296-009-1305-9.
4. Bailey AJ, Tarlton JF, Van der Stappen J, Sims TJ, Messina A. The continuous elongation technique for severe Dupuytren's disease. A biochemical mechanism. J Hand Surg Br. 1994;19:522-527.
5. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie disease. Urology. 2007;69:1181-1184.
6. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie disease: a preliminary report. BJU Int. 2001;88:63-67.
7. Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, Kadowitz PJ, Hellstrom WJ. A rat model of Peyronie disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol. 2000;163:1992-1998.
8. Bodner H, Howard AH, Kaplan JH. Peyronie disease; cortisonehyaluronidase- hydrocortisone therapy. Trans West Sect Am Urol Assoc. 1953;20:32-35.
9. Carson CC 3rd, Coughlin PW. Radiation therapy for Peyronie disease: is there a place? J Urol. 1985;134:684-686.
10. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie disease. Urology. 2007;69:950-954.
11. Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352-1356.
12. Choi HK, Pokharel YR, Lim SC, Han HK, Ryu CS, Kim SK, Kwak MK, Kang KW. Inhibition of liver fibrosis by solubilized coenzyme Q10: role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. Toxicol Appl Pharmacol. 2009; 240:377-384.
13. Citron N, Messina JC. The use of skeletal traction in the treatment of severe primary Dupuytren's disease. J Bone Joint Surg Br. 1998; 80:126-129.
14. Desanctis PN, Furey CA Jr. Steroid injection therapy for Peyronie disease: a 10-year summary and review of 38 cases. J Urol. 1967; 97:114-116.
15. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, Vespasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie disease. J Urol. 2004;171:1605-1608.
16. Doong H, Dissanayake S, Gowrishankar TR, LaBarbera MC, Lee RC. The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. J Burn Care Rehabil. 1996;17:497-514.
17. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25:89-94.
18. El-Mofty M, El-Darouti M, Rasheed H, Bassiouny DA, Abdel-Halim M, Zaki NS, El-Hanafy G, El-Hadidi H, Azzam O, El-Ramly A, Fawzy M. Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative. J Dermatolog Treat. 2010;22:31-37.
19. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997;158:2284-2290.
20. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie disease. BJU Int. 2006;97:625-633.
21. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide. 2002;6:283-294.
22. Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie disease-a placebo-controlled pilot study. J Sex Med. 2007;4:477-484.
23. Fricke RE, Varney JH. Peyronie disease and its treatment with radium. J Urol. 1948;59:627-630.
24. Gelbard MK, Dorey F, James K. The natural history of Peyronie disease. J Urol. 1990;144:1376-1379.
25. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie disease: a double-blind study. J Urol. 1993;149:56-58.
26. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, Mondaini N. Use of penile extender device in the treatment of penile curvature as a result of Peyronie disease. Results of a phase II prospective study. J Sex Med. 2009; 6:558-566.
27. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie disease. Nat Clin Pract Urol. 2005;2:291-297.
28. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie disease: a doubleblind, placebo controlled trial. J Urol. 2007;177:972-975.
29. Hamm R, McLarty E, Ashdown J, Natale S, Dickinson A. Peyronie disease-the Plymouth experience of extracorporeal shockwave treatment. BJU Int. 2001;87:849-852.
30. Hashimoto K, Hisasue S, Kato R, Kobayashi K, Shimizu T, Tsukamoto T. Outcome analysis for conservative management of Peyronie disease. Int J Urol. 2006;13:244-247.
31. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, Venable D, Honig S, McCullough A, Hakim LS, Nehra A, Templeton LE, Pryor JL. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie disease. J Urol. 2006;176:394-398.
32. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie disease: a randomized and prospective study. Urology. 2006;67:1038-1042.
33. Incrocci L, Hop WC, Seegenschmiedt HM. Radiotherapy for Peyronie Disease: a European survey. Acta Oncol. 2008;47:1110-1112.
34. Incrocci L, Wijnmaalen A, Slob AK, Hop WC, Levendag PC. Lowdose radiotherapy in 179 patients with Peyronie disease: treatment outcome and current sexual functioning. Int J Radiat Oncol Biol Phys. 2000;47:1353-1356.
35. Isaac C, Carvalho VF, Paggiaro AO, de Maio M, Ferreira MC. Intralesional pentoxifylline as an adjuvant treatment for perioral post-burn hypertrophic scars. Burns. 2010;36:831-835.
36. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71:343S-348S.
37. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie disease and erectile dysfunction. J Urol. 1997;158:1388-1390.
38. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie disease: a prospective, single-center, non- placebo-controlled study. J Sex Med. 2008;5:180-187.
39. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie disease. J Urol. 2002;168:1075-1079.
40. Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000; 12:169-175.
41. Koren H, Alth G, Schenk GM, Jindra RH. Induratio penis plastica: effectivity of low-dose radiotherapy at different clinical stages. Urol Res. 1996;24:245-248.
42. Levine L. Comment on 'Topical verapamil HCL, topical trifluoroperazine, and topical magnesium sulfate for the treatment of Peyronie disease-a placebo-controlled pilot study'. J Sex Med. 2007;4: 1081-1082.
43. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie disease. J Urol. 2002;168: 621-625; discussion 625-626.
44. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie disease. J Urol. 1994;151:1522-1524.
45. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie disease: a single-center pilot study. J Sex Med. 2008;5:1468-1473.
46. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168:2483-2485.
47. Mirone V, Imbimbo C, Palmieri A, Fusco F. Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica. Eur Urol. 1999;36:327-330.
48. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350-2353.
49. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie disease. J Urol. 2006;175:2115-2118; discussion 2118.
50. Musitelli S, Bossi M, Jallous H. A brief historical survey of ''Peyronie disease.'' J Sex Med. 2008;5:1737-1746.
51. Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie disease. J Sex Med. 2008;5:1985-1990.
52. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie disease. Eur Urol. 2009;56:363-369.
53. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, Schuppan D. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut. 2002;50:241-247.
54. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie disease plaque: a long-term single-blind study. Urology. 1998;51:620-626.
55. Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A. 1996;93:5478-5482.
56. Rothfeld SH, Murray W. The treatment of Peyronie disease by iontophoresis of C21 esterified glucocortocoids. J Urol. 1967;97: 874-875.
57. Safarinejad MR. Efficacy and safety of omega-3 for treatment of earlystage Peyronie disease: a prospective, randomized, double-blind placebo-controlled study. J Sex Med. 2009;6:1743-1754.
58. Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie disease: a double-blind, placebocontrolled randomized study. Int J Impot Res. 2010;22:298-309.
59. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A doubleblind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie disease. BJU Int. 2009;106:240-248.
60. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178:1398-1403; discussion 1403.
61. Schandene L, Vandenbussche P, Crusiaux A, Alegre ML, Abramowicz D, Dupont E, Content J, Goldman M. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology. 1992;76:30-34.
62. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie disease: results of a large survey. BJU Int. 2001;88:727-730.
63. Scott WW, Scardino PL. A new concept in the treatment of Peyronie disease. South Med J. 1948;41:173-177.
64. Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, Lin CS, Lue TF. Pentoxifylline attenuates transforming growth factor-beta1- stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med. 2010;7:2077-2085.
65. Sieg A, Wascotte V. Diagnostic and therapeutic applications of iontophoresis. J Drug Target. 2009;17:690-700.
66. Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie disease. J Sex Med. 2008;5:2179-2184.
67. Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y, Fujiwara T, Kamoi K, Miki T. Nicardipine vs. saline injection as treatment for Peyronie disease: a prospective, randomized, singleblind trial. J Sex Med. 2010;7:3743-3749.
68. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie disease. J Urol. 1999;162:2003-2005.
69. Thai A, Xiao J, Ammit AJ, Rohanizadeh R. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims. Int J Pharm. 2010;389:41-52.
70. Tuygun C, Ozok UH, Gucuk A, Bozkurt IH, Imamoglu MA. The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie disease. Int Urol Nephrol. 2009;41:113-118.
71. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229-244.
72. van Hinsbergh VW, Scheffer MA. Effect of propionyl-L-carnitine on human endothelial cells. Cardiovasc Drugs Ther. 1991;5(suppl 1):97-105.
73. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530-535; discussion 535-536.
74. Winter CC, Khanna R. Peyronie disease: results with dermo-jet injection of dexamethasone. J Urol. 1975;114:898-900.